Alimera resubmits NDA
Alimera Sciences (ALIM) resubmits its NDA for ILUVIEN after receiving a CRL from the regulator in October.
The product is approved for sale in the UK, Portugal, France, Germany and Spain, but is commercially available only in the UK and Germany.
Consensus revenue estimates for 2014 and 2015 are $13.7M and $36.2M, respectively.
73 mutual funds have positions, up from 23 a year earlier.